Go to content
UR Home

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Herrlinger, Ulrich ; Tzaridis, Theophilos ; Mack, Frederic ; Steinbach, Joachim Peter ; Schlegel, Uwe ; Sabel, Michael ; Hau, Peter ; Kortmann, Rolf-Dieter ; Krex, Dietmar ; Grauer, Oliver ; Goldbrunner, Roland ; Schnell, Oliver ; Bähr, Oliver ; Uhl, Martin ; Seidel, Clemens ; Tabatabai, Ghazaleh ; Kowalski, Thomas ; Ringel, Florian ; Schmidt-Graf, Friederike ; Suchorska, Bogdana ; Brehmer, Stefanie ; Weyerbrock, Astrid ; Renovanz, Miriam ; Bullinger, Lars ; Galldiks, Norbert ; Vajkoczy, Peter ; Misch, Martin ; Vatter, Hartmut ; Stuplich, Moritz ; Schäfer, Niklas ; Kebir, Sied ; Weller, Johannes ; Schaub, Christina ; Stummer, Walter ; Tonn, Jörg-Christian ; Simon, Matthias ; Keil, Vera C. ; Nelles, Michael ; Urbach, Horst ; Coenen, Martin ; Wick, Wolfgang ; Weller, Michael ; Fimmers, Rolf ; Schmid, Matthias ; Hattingen, Elke ; Pietsch, Torsten ; Coch, Christoph ; Glas, Martin



Abstract

Background There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter. In the CeTeG/NOA-09 trial, we aimed to further investigate the effect of ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons